Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy
Status:
Completed
Trial end date:
2003-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of
intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to
epoetin alfa among anemic cancer patients receiving chemotherapy.
Phase:
Phase 4
Details
Lead Sponsor:
Watson Pharmaceuticals
Treatments:
Epoetin Alfa Ferric Compounds Ferric gluconate Iron